Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis
Uro-Oncology
Related content
Uro-Oncology
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Prostate Cancer Prostatic Dis
George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ
doi: 10.1038/s41391-024-00816-0
Uro-Oncology
Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer
Prostate
Büttner T, Klümper N, Weiten R, Lossin P, Latz S, Jacobs C, Ritter M, Hauser S, Ellinger J, Krausewitz P
doi: 10.1002/pros.24747
Uro-Oncology
Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience
Prostate
Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H
doi: 10.1002/pros.24880
Uro-Oncology
Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting
J Am Geriatr Soc
Wenzel M, Hoeh B, Wagner N, Koll F, Siech C, Humke C, Steuber T, Graefen M, Tilki D, Kluth L, Traumann M, Banek S, Chun FKH, Mandel P
doi: 10.1111/jgs.19045
Uro-Oncology
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Eur Urol
Roy S, Fervaha G, Spratt DE, Sun Y, Kishan AU, Loblaw A, Malone S, Ong M, Saad F, Wallis CJD, Morgan SC
doi: 10.1016/j.eururo.2024.03.018
Uro-Oncology
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Eur Urol
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR
doi: 10.1016/j.eururo.2024.03.036
COMMENTED
Uro-Oncology
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Freedland SJ, Mulhall JP, Gleave M, Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N
doi: 10.1016/j.eururo.2025.02.006
Uro-Oncology
Androgen Deprivation Therapy and Newly Developed Neovascular Age-Related Macular Degeneration Risk in Patients with Prostate Cancer
J Clin Med
Ha JS, Kim DK, Lee HS, Jeon S, Jeon J, Kim D, Kim JS, Kim B, Kim M, Cho KS
doi: 10.3390/jcm13102978
Uro-Oncology
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
Lancet Oncol
Kishan AU, Sun Y, Tree AC, Hall E, Dearnaley D, Catton CN, Lukka HR, Pond G, Lee WR, Sandler HM, Feng FY, Nguyen PL, Incrocci L, Heemsbergen W, Pos FJ, Horwitz E, Wong JK, Hoffman KE, Hassanzadeh C, Kuban DA, Arcangeli S, Sanguineti G, Supiot S, Crehange G, Latorzeff I, Kalbasi TR, Steinberg ML, Valle LF, Loblaw A, Nikitas J, Roy S, Zaorsky NG, Jia AY, Spratt DE
doi: 10.1016/S1470-2045(25)00034-8